MD MBA - Onconetix Chief Officer
| ONCO Stock | USD 0.80 0.29 26.61% |
Executive
MD MBA is Chief Officer of Onconetix
| Address | 201 East Fifth Street, Cincinnati, OH, United States, 45202 |
| Phone | 513 620 4101 |
| Web | https://onconetix.gcs-web.com |
Onconetix Management Efficiency
The company has return on total asset (ROA) of (0.2185) % which means that it has lost $0.2185 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (17.5848) %, meaning that it created substantial loss on money invested by shareholders. Onconetix's management efficiency ratios could be used to measure how well Onconetix manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to grow to -4.59. In addition to that, Return On Capital Employed is likely to drop to -0.53. At this time, Onconetix's Total Assets are very stable compared to the past year. As of the 26th of November 2024, Non Current Assets Total is likely to grow to about 87.1 M, while Other Assets are likely to drop 0.80.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Spyridon Leousis | Capital Clean Energy | 45 | |
| Dani Ashkenazi | Tower Semiconductor | 61 | |
| Rafi Mor | Tower Semiconductor | 60 | |
| Lei Qin | Tower Semiconductor | N/A | |
| Rohn Crabtree | Verde Clean Fuels | 69 | |
| George Burdette | Verde Clean Fuels | N/A | |
| Nikolaos Kalapotharakos | Capital Clean Energy | 49 | |
| Kirsty Gill | Arm Holdings plc | 52 | |
| Eleni Tsoukala | Capital Clean Energy | 46 | |
| John Doyle | Verde Clean Fuels | 63 | |
| Vincent Marchese | Verde Clean Fuels | N/A | |
| Brian Gallagher | Capital Clean Energy | 54 | |
| Noit LevyKaroubi | Tower Semiconductor | 39 | |
| Richard Grisenthwaite | Arm Holdings plc | 55 | |
| Charlotte Eaton | Arm Holdings plc | N/A | |
| Drew Henry | Arm Holdings plc | N/A | |
| William Abbey | Arm Holdings plc | 53 | |
| Shannon Linden | Verde Clean Fuels | 43 | |
| Laura Bartels | Arm Holdings plc | N/A | |
| Ian Thornton | Arm Holdings plc | N/A | |
| Spencer Collins | Arm Holdings plc | 42 | |
Management Performance
| Return On Equity | -17.58 | ||||
| Return On Asset | -0.22 |
Onconetix Leadership Team
Elected by the shareholders, the Onconetix's board of directors comprises two types of representatives: Onconetix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Onconetix. The board's role is to monitor Onconetix's management team and ensure that shareholders' interests are well served. Onconetix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Onconetix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, Chief Officer | ||
| Christian Bruhlmann, Chief Officer | ||
| Dr Very, Senior Development | ||
| Theodore Yoho, Head Development | ||
| Erin Henderson, Consultant | ||
| Brian Price, Head Strategy | ||
| Ali Fattom, Head Discovery | ||
| MBA MA, Senior Development | ||
| Ralph Schiess, Interim Officer | ||
| Bruce Harmon, Chief Officer | ||
| Andrew Skibo, Global Operations | ||
| Karina Fedasz, Interim Officer |
Onconetix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Onconetix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -17.58 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (3.00) % | ||||
| Current Valuation | 23.39 M | ||||
| Shares Outstanding | 8.29 M | ||||
| Shares Owned By Insiders | 57.93 % | ||||
| Shares Owned By Institutions | 7.86 % | ||||
| Number Of Shares Shorted | 21.7 K | ||||
| Price To Book | 0.31 X | ||||
| Price To Sales | 6.18 X |
Pair Trading with Onconetix
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Onconetix position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Onconetix will appreciate offsetting losses from the drop in the long position's value.Moving together with Onconetix Stock
| 0.63 | A | Agilent Technologies | PairCorr |
| 0.7 | ME | 23Andme Holding | PairCorr |
| 0.74 | VALN | Valneva SE ADR | PairCorr |
| 0.8 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Onconetix Stock
| 0.72 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.61 | RNXT | RenovoRx | PairCorr |
| 0.38 | NXGLW | NexGel Warrant | PairCorr |
| 0.37 | KEP | Korea Electric Power | PairCorr |
The ability to find closely correlated positions to Onconetix could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Onconetix when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Onconetix - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Onconetix to buy it.
The correlation of Onconetix is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Onconetix moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Onconetix moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Onconetix can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Onconetix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Onconetix Stock, please use our How to Invest in Onconetix guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Onconetix. If investors know Onconetix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Onconetix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (109.20) | Revenue Per Share 2.892 | Return On Assets (0.22) | Return On Equity (17.58) |
The market value of Onconetix is measured differently than its book value, which is the value of Onconetix that is recorded on the company's balance sheet. Investors also form their own opinion of Onconetix's value that differs from its market value or its book value, called intrinsic value, which is Onconetix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Onconetix's market value can be influenced by many factors that don't directly affect Onconetix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Onconetix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Onconetix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Onconetix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.